Advertisement

Diabetologia

, 40:B89 | Cite as

New insulins and other possible therapeutic approaches

  • J. Johannesen
  • K. F. Petersen
  • M. Berger
  • C. Binder
Article

Keywords

Insulin Lispro Regular Insulin Pramlintide Short Acting Insulin Fructosamine Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Zinman B, Tildesley H, Chiasson JH, Tsui E, Strack T (1997) Insulin lispro in CSII: Results of a double-blind crossover study. Diabetes 46: 440–443CrossRefPubMedGoogle Scholar
  2. 2.
    Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn’t. BMJ 312: 71–72PubMedGoogle Scholar
  3. 3.
    Young AA, Wang MW, Gedulin B, Rink TJ, Pittner R, Beaumont K (1995) Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity. Metabolism 44: 1581–1589CrossRefPubMedGoogle Scholar
  4. 4.
    Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A (1996) Effect of 14 days’ subcutaneous administration of the human amylin analogue, pramlintide (AC 137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 39: 492–499CrossRefPubMedGoogle Scholar
  5. 5.
    Thompson RG, Pearson L, Gottlieb A, Kolterman OG (1996) Pramlintide, an analog of human amylin, reduced fructosamine in patients with type 1 diabetes. Diabetes 45: [Suppl 2] 222A (Abstract)Google Scholar
  6. 6.
    Wahren J, Johansson B-L, Wallberg-Henriksson H, Linde B, Fernqvist-Forbes E, Zierath J R (1996) C-peptide revisited — new physiological effects and therapeutic implications. J Int Med 240: 115–124CrossRefGoogle Scholar
  7. 7.
    Zenobi PD, Glatz Y, Keller A et al. (1994) Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin resistant diabetes type A. Eur J Endocrinol 131: 251–257CrossRefPubMedGoogle Scholar
  8. 8.
    Dunger DB, Cheetham TD, Crowne EC (1995) Insulin growth factors (IGFs) and IGFI treatment in the adolescent with insulin-dependent diabetes mellitus. Metabolism 44: 119–123CrossRefPubMedGoogle Scholar
  9. 9.
    Moses AC, Young SC, Morrow LA, O’Brien M, Clemmons DR (1996) Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycaemic control in type II diabetes. Diabetes 45: 91–100CrossRefPubMedGoogle Scholar
  10. 10.
    Mitragotri S, Blankschtein D, Langer R (1995) Ultrasound-mediated transdermal protein delivery. Science 269: 850–853CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1997

Authors and Affiliations

  • J. Johannesen
    • 1
  • K. F. Petersen
    • 2
  • M. Berger
    • 3
  • C. Binder
    • 1
  1. 1.Steno Diabetes CenterGentofteDenmark
  2. 2.Department of Internal MedicineYale University School of MedicineNew HavenUSA
  3. 3.Heinrich Heine UniversitätDüsseldorfGermany

Personalised recommendations